Dr. Griguer's laboratory research focuses on mechanistic studies of glioma initiation and progression, especially the contributions from the mitochondria. Over the past 10 years, as PI on several university- and NIH-funded grants, I laid the ground work in our understanding on how mitochondria play an essential role in tumor chemo-resistance and survival in glioma. My research efforts have helped to delineate how these processes are regulated at the molecular level, and we have identified Cytochrome c Oxidase as a main player in the regulation of chemo-resistance through a bioenergetic switch from glycolysis to oxidative phosphorylation.
We identified Cytochrome C Oxidase subunit 4 isoforms (COX4) as significant markers of these drastic phenotypic changes during TMZ treatment. Currently I am the PI on an ongoing NINDS funded prospective and prognostic biomarker trial which has enrolled 152 glioblastoma patients undergoing standard of care (19 clinical sites) from which cytochrome c oxidase activity is currently assayed against the standard biomarker O6-methylguanine–DNA methyltransferase.
Complete publications | Pubmed